Registration now open: Beyond the vein, see
central vascular access through the eyes of the patient
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV; OTCQX: CVALF), a leader in advanced medical technologies,
proudly announces the opening of registration for a unique,
patient-led webinar. The event, scheduled for Wednesday, September
27, 2023, from 1-2 PM EST, is designed to provide attendees with a
profound look into the patient’s world – living with central
vascular access devices.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230925181300/en/
Covalon presents a new webinar titled
“Central Vascular Access Devices: Key Considerations from the
Patient’s Perspective”, featuring speakers Jessika Buehne and
Chalice Richert, to be held on Wednesday, September 27, 2023, at 1
– 2 PM EST. (Photo: Business Wire)
Guided by the firsthand experiences of Jessika Buehne and
Chalice Richert, who are both clinically trained and have navigated
the complexities of central vascular access devices, the webinar
aims to underscore the necessity of understanding the patient
experience and the importance of compassion in device management
and patient care.
“The approach Covalon is taking to listen and amplify the voice
of patients speaks volumes,” said Jessika Buehne. “It shows we
aren’t forgotten or aren’t just another ID number to a medical
product. Knowing hospitals and device companies are listening gives
me hope.” Chalice Richert added, “Finding the right device for your
line and skin can make all the difference. It is encouraging that
Covalon is considering how patient needs can differ, and I’m
excited for the opportunity share my experience, in hopes that it
helps others living with a central line.”
Key takeaways from the webinar titled: “Central Vascular Access
Devices: Key Considerations from the Patient’s Perspective”
include:
- Recognizing the importance of patient-centered device
selection
- Special considerations for long-term IV access
- Guidance for finding the right device for you, your loved one,
or patient
- Best practices for patient-care team engagement
- Intimate stories, first-hand patient perspectives, and
real-life experiences
- A dynamic opportunity to share, learn, discuss, and
interact
Webinar Details:
Title: Central Vascular Access Devices: Key
Considerations from the Patient’s Perspective
Speakers: Jessika Buehne and Chalice Richert
Date: Wednesday, September 27, 2023, 1 – 2 PM EST
Registration Link: Central Vascular Access Devices
Hashtags: #MARSI, #infectionprevention,
#compassionatecare
Choosing the right medical dressing for a patient can make the
difference between pain vs comfort, infection vs healing, skin
injury vs skin integrity.
Covalon’s soft silicone dressings provide gentle,
non-compromisingly effective care:
- CovaClear® IV – utilizes soft silicone adhesive technology to
help protect patients from skin injuries, but does not incorporate
antimicrobials, for use with patients who either do not require or
cannot tolerate antimicrobials.
- IV Clear® - the world’s only dual-antimicrobial vascular access
dressing that offers complete transparency at and around the
insertion site for easy daily assessment. It also utilizes soft
silicone adhesive technology to minimize skin injuries and preserve
skin barrier functions, and incorporates safe amounts of
antimicrobials, without sacrificing efficacy, to protect against
chemical irritation.
- SurgiClear® - the world's only dual-antimicrobial clear
postoperative dressing that provides full surgical site visibility,
allowing for visual site inspection and thus eliminating the need
for early and multiple dressing removals.
For healthcare providers who are not able to attend the webinar
but are interested in learning more about Covalon’s solutions,
visit www.covalon.com or follow Covalon on LinkedIn, Facebook,
Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon’s name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur”, or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management’s expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the “Risks
and Uncertainties” section of our management’s discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which is available on the Company’s
profile at www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230925181300/en/
To learn more about Covalon:
Brian Pedlar, CEO, Covalon Technologies Ltd. Email:
bpedlar@covalon.com Phone: 905.568.8400 x 233 Toll-Free:
1.877.711.6055 Website: https://covalon.com/ Twitter: @covalon
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Nov 2023 to Nov 2024
